StockData

Fulcrum Therapeutics vs Wave Life Sciences

FULC and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FULC and WVE compare

Wave Life Sciences is the larger company, worth 2.0 times as much as Fulcrum Therapeutics ($560M against $286M).

Wave Life Sciences scores higher on the StockData Score (10 against 8 for Fulcrum Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFULCWVE
Size and price
Market cap$286M$560M
Share price$3.75$2.84
Change, 1 year−56.6%−59.9%
Change, 5 years−75.1%−28.8%
Beta (5Y)1.361.86
Employees55317
StockData Score
Total score810 (better)
Valuation score13 (better)
Growth score01 (better)
Performance score11
Health score6 (better)5
Dividend score00
Valuation
P/S–7.9×
P/B0.9× (better)1.4×
FCF yield−23.1% (better)−37.2%
Fair value–$5.23
Margin of safety–45.7%
Growth
Revenue growth, 5Y average–16.3%
Profitability
Operating margin–−321%
Net margin–−297%
FCF margin–−294%
Return on equity−32.4% (better)−80.0%
Return on invested capital−35.0%–
Financial health
Debt / equity0.000.00
Current ratio31.35 (better)8.38
Altman Z-score10.37 (better)−1.30
Piotroski F-score33
Dividends and buybacks
Buyback yield−1.5%–
Shareholder yield−1.5%0.00% (better)
Ownership
Held by institutions112%92.6%
Held by insiders34.7%23.1%
Insider net buying, 12 months−$57.5M$66.5M (better)
Superinvestors holding–1
Short interest, % of float12.9%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.